Today, Gubra announces the signing of an agreement with Hemab concerning a peptide collaboration. Under the terms of this pre-collaboration agreement, Gubra will start working on identifying peptide modulators suitable as a treatment for certain bleeding disorders. Gubra will utilize its streaMLine peptide platform to develop a clinical candidate which will subsequently be handed over to Hemab for further development.
Under the pre-collaboration agreement, Gubra will receive a single digit DKK million payment in Q3 2023. A full collaboration agreement is being finalised and will be signed at a later stage once final terms have been agreed to. This final agreement will lay out further terms for the collaboration including further short and long term milestone payments and royalties.
“We are excited to start working on this program with Hemab. Bleeding disorders are outside of Gubra’s normal metabolic disease focus, so it is a testimony that our streaMLine platform can be used to develop peptide drug candidates to a very broad range of diseases”, said Henrik Blou, CEO of Gubra A/S. “Speed is of the essence for this collaboration hence we are starting up work immediately under this pre-collaboration agreement, and once a final collaboration agreement is ready it will be signed by the parties and further details of the final agreement will be disclosed.“